Serum hepatitis B surface antigen levels in the natural history of chronic hepatitis B infection

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 11-12, 2011, Pages 1337-1346

  Jang, J W ^a   Yoo, S H ^a   Kwon, J H ^a   You, C R ^a   Lee, S ^b   Lee, J H ^b   Chung, K W ^a  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIGEN DETECTION; ANTIGEN FUNCTION; ARTICLE; BLOOD LEVEL; CHILD PUGH CLASS A; CHILD PUGH CLASS B; CHILD PUGH CLASS C; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE CARRIER; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KOREA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; DNA, VIRAL; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; REGRESSION ANALYSIS; TIME FACTORS; YOUNG ADULT;

EID: 81355146411     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04888.x     Document Type: Article

References (23)

1. Chu CM, Liaw YF,. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007; 45: 1187-92.
2. Deguchi M, Yamashita N, Kagita M, et al. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods 2004; 115: 217-22.
3. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004; 126: 1750-8.
4. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44: 675-84.
5. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-7.
6. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-50.
7. Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5: 1462-8.
8. Chan HL, Wong VW, Chim AM, Chan HY, Wong GL, Sung JJ,. Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B. Aliment Pharmacol Ther 2010; 32: 1323-31.
9. Jaroszewicz J, Calle Serrano B, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol 2010; 52: 514-22.
10. Sugiyama M, Tanaka Y, Kato T, et al. Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens. Hepatology 2006; 44: 915-24.
11. Lee JM, Ahn SH, Chang HY, et al. Reappraisal of HBV genotypes and clinical significance in Koreans using MALDI-TOF mass spectrometry. Kor J Hepatol 2004; 10: 260-70.
12. Bae SH, Yoon SK, Jang JW, et al. Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea. J Korean Med Sci 2005; 20: 816-20.
13. Song BC, Cui XJ, Kim HU, Cho YK,. Sequential accumulation of the basal core promoter and the precore mutations in the progression of hepatitis B virus-related chronic liver disease. Intervirology 2006; 49: 266-73.
14. Yoo BC, Park JW, Kim HJ, Lee DH, Cha YJ, Park SM,. Precore and core promoter mutations of hepatitis B virus and hepatitis B e antigen-negative chronic hepatitis B in Korea. J Hepatol 2003; 38: 98-103.
15. Lee KS, Kim DJ,. Management of chronic hepatitis B. Kor J Hepatol 2007; 13: 447-88.
16. Lok AS, McMahon BJ,. Chronic hepatitis B. Hepatology 2007; 45: 507-39.
17. Ayoub WS, Keeffe EB,. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther 2008; 28: 167-77.
18. Korean Liver Cancer Study Group and National Cancer Center, Korea. Practice guidelines for management of hepatocellular carcinoma 2009. Kor J Hepatol 2009; 15: 391-423.
19. Thompson AJ, Nguyen T, Iser D, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010; 51: 1933-44.
20. Chan HL, Wong VW, Wong GL, Tse CH, Chan HY, Sung JJ,. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology 2010; 52: 1232-41.
21. Nguyen T, Thompson AJ, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol 2010; 52: 508-13.
22. Manesis EK, Papatheodoridis GV, Tiniakos DG, et al. Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. J Hepatol 2011; 55: 61-8.
23. Thomas H, Lemon S, Zuckerman AJ,. Viral Hepatitis, 3rd edn. Massachusetts, USA: Blackwell Publishing, 2005.